WO2004024757A3 - Modified pna molecules - Google Patents

Modified pna molecules Download PDF

Info

Publication number
WO2004024757A3
WO2004024757A3 PCT/DK2003/000588 DK0300588W WO2004024757A3 WO 2004024757 A3 WO2004024757 A3 WO 2004024757A3 DK 0300588 W DK0300588 W DK 0300588W WO 2004024757 A3 WO2004024757 A3 WO 2004024757A3
Authority
WO
WIPO (PCT)
Prior art keywords
pna molecules
modified pna
invention concerns
drugs
pna
Prior art date
Application number
PCT/DK2003/000588
Other languages
French (fr)
Other versions
WO2004024757A2 (en
Inventor
Palle Rasmussen
Niels Montano Frandsen
Marlene Nyborg
Frank Winther Rasmussen
Ramin Hamzavi
Peter Eigild Nielsen
Soeren Kjaerulff
Original Assignee
Santaris Pharma As
Palle Rasmussen
Niels Montano Frandsen
Marlene Nyborg
Frank Winther Rasmussen
Ramin Hamzavi
Peter Eigild Nielsen
Soeren Kjaerulff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As, Palle Rasmussen, Niels Montano Frandsen, Marlene Nyborg, Frank Winther Rasmussen, Ramin Hamzavi, Peter Eigild Nielsen, Soeren Kjaerulff filed Critical Santaris Pharma As
Priority to CA002498772A priority Critical patent/CA2498772A1/en
Priority to EP03794821A priority patent/EP1543019A2/en
Priority to AU2003260289A priority patent/AU2003260289A1/en
Publication of WO2004024757A2 publication Critical patent/WO2004024757A2/en
Publication of WO2004024757A3 publication Critical patent/WO2004024757A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns novel drugs for use in combating various diseases. More particularly the invention concerns peptide nucleic acid (PNA) drugs, which are optionally modified in order to obtain novel PNA molecules with cell-specific delivery.
PCT/DK2003/000588 2002-09-11 2003-09-11 Modified pna molecules WO2004024757A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002498772A CA2498772A1 (en) 2002-09-11 2003-09-11 Modified pna molecules
EP03794821A EP1543019A2 (en) 2002-09-11 2003-09-11 Modified pna molecules
AU2003260289A AU2003260289A1 (en) 2002-09-11 2003-09-11 Modified pna molecules

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200201334 2002-09-11
DKPA200201334 2002-09-11
DKPA200201786 2002-11-19
DKPA200201786 2002-11-19
DKPA200201956 2002-12-20
DKPA200201956 2002-12-20
DKPA200300600 2003-04-16
DKPA200300600 2003-04-16

Publications (2)

Publication Number Publication Date
WO2004024757A2 WO2004024757A2 (en) 2004-03-25
WO2004024757A3 true WO2004024757A3 (en) 2004-04-29

Family

ID=31999319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000588 WO2004024757A2 (en) 2002-09-11 2003-09-11 Modified pna molecules

Country Status (4)

Country Link
EP (1) EP1543019A2 (en)
AU (1) AU2003260289A1 (en)
CA (1) CA2498772A1 (en)
WO (1) WO2004024757A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008242583B2 (en) * 2007-04-23 2013-10-10 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
EP2231194B1 (en) 2007-12-04 2017-02-22 Alnylam Pharmaceuticals Inc. Folate-irna conjugates
US20090247608A1 (en) 2007-12-04 2009-10-01 Alnylam Pharmaceuticals, Inc. Targeting Lipids
CA2832553A1 (en) 2011-04-08 2012-10-11 Srinivas RAPIREDDY Conformationally-preorganized, minipeg-containing gamma-peptide nucleic acids
DK2751270T3 (en) 2011-08-29 2018-10-29 Ionis Pharmaceuticals Inc OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
US10370415B2 (en) 2013-04-11 2019-08-06 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
US10221216B2 (en) 2013-04-11 2019-03-05 Carnegie Mellon University Template-directed γPNA synthesis process and γPNA targeting compounds
DK3137476T3 (en) 2014-04-28 2019-11-18 Ionis Pharmaceuticals Inc LINKER-MODIFIED OLIGOMER COMPOUNDS
RS59182B1 (en) 2014-05-01 2019-10-31 Ionis Pharmaceuticals Inc Compositions and methods for modulating complement factor b expression
EP3974534A1 (en) 2014-05-01 2022-03-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
BR112016022855B1 (en) 2014-05-01 2022-08-02 Ionis Pharmaceuticals, Inc COMPOUNDS AND COMPOSITIONS TO MODULATE THE EXPRESSION OF PKK AND ITS USES
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
DK3320094T3 (en) 2015-07-10 2022-05-23 Ionis Pharmaceuticals Inc MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
US20180273577A1 (en) 2015-09-24 2018-09-27 Ionis Pharmaceuticals, Inc. Modulators of kras expression
DK4119569T3 (en) 2015-11-06 2024-08-12 Ionis Pharmaceuticals Inc Conjugated antisense compounds for use in therapy
PE20181180A1 (en) 2015-11-06 2018-07-20 Ionis Pharmaceuticals Inc MODULATE THE EXPRESSION OF APOLIPOPROTEIN (a)
UY37146A (en) 2016-03-07 2017-09-29 Arrowhead Pharmaceuticals Inc ADDRESSING LINKS FOR THERAPEUTIC COMPOUNDS
FI3484524T3 (en) 2016-07-15 2023-01-13 Compounds and methods for modulation of smn2
SG10201912835QA (en) 2016-09-02 2020-02-27 Arrowhead Pharmaceuticals Inc Targeting ligands
CA3076694A1 (en) 2016-09-26 2018-03-29 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
JP2020511550A (en) * 2017-03-23 2020-04-16 トゥルーコード ジーン リペアー， インコーポレイテッド Peptide nucleic acid (PNA) monomer with orthogonal protected ester moieties
JOP20190215A1 (en) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc Modulators of pcsk9 expression
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
MX2020007369A (en) 2018-01-15 2020-10-28 Ionis Pharmaceuticals Inc Modulators of dnm2 expression.
WO2019157531A1 (en) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
CN112041446B (en) 2018-05-09 2022-08-30 Ionis制药公司 Compounds and methods for reducing FXI expression
EP3833397A4 (en) 2018-08-08 2023-06-14 Arcturus Therapeutics, Inc. Compositions and agents against nonalcoholic steatohepatitis
AR114551A1 (en) 2018-08-13 2020-09-16 Alnylam Pharmaceuticals Inc COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE
TW202423454A (en) 2018-09-19 2024-06-16 美商Ionis製藥公司 Modulators of pnpla3 expression
WO2021074772A1 (en) 2019-10-14 2021-04-22 Astrazeneca Ab Modulators of pnpla3 expression
JOP20220201A1 (en) 2020-02-28 2023-01-30 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2
EP4136092B1 (en) 2020-11-18 2024-07-31 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
CA3233755A1 (en) 2021-10-01 2023-04-06 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053801A1 (en) * 1997-05-28 1998-12-03 Isis Pharmaceuticals, Inc. Conjugated peptide nucleic acids having enhanced cellular uptake

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053801A1 (en) * 1997-05-28 1998-12-03 Isis Pharmaceuticals, Inc. Conjugated peptide nucleic acids having enhanced cellular uptake

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAMIN HAMZAVI ET AL: "Modulation of the Pharmacokinetic Properties of PNA: Preparation of Galactosyl, Mannosyl, Fucosyl, N-Acetylgalactosaminyl, and N-Acetylglucosaminyl Derivatives of Aminoethylglycine Peptide Nucleic Acid Monomers and Their Incorporation into PNA Oligomers", BIOCONJUGATE CHEM., vol. 14, 2003, pages 941 - 954, XP002270930 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US9145558B2 (en) 2013-05-01 2015-09-29 Isis Pharmaceuticals, Inc. Compositions and methods for modulating HBV expression
US9163239B2 (en) 2013-05-01 2015-10-20 Isis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein C-III expression
US9181550B2 (en) 2013-05-01 2015-11-10 Isis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US9181549B2 (en) 2013-05-01 2015-11-10 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US11851655B2 (en) 2013-05-01 2023-12-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression

Also Published As

Publication number Publication date
EP1543019A2 (en) 2005-06-22
AU2003260289A1 (en) 2004-04-30
WO2004024757A2 (en) 2004-03-25
CA2498772A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
WO2004024757A3 (en) Modified pna molecules
EP1750771A4 (en) Pancreatic islet microrna and methods for inhibiting same
WO2005014850A3 (en) Systems and methods for analyzing nucleic acid sequences
WO2004052177A3 (en) Cell-based therapies for ischemia
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2006074351A3 (en) Reversible nucleotide terminators and uses thereof
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
WO2002014485A3 (en) Kallikrein gene
WO2008016906A3 (en) 3'-phosphate-labeled nucleotide analogs and their use for sequencing a nucleic acid
WO2005000888A3 (en) NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF
WO2006000213A3 (en) Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
WO2006076628A3 (en) Compositions comprising promoter sequences and methods of use
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2003029422A3 (en) Noonan syndrome gene
WO2006081463A3 (en) Thermococcus zilligii dna polymerases and variants thereof
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
AU2003232036A1 (en) Nanoarchaeum nucleic acid molecule
NO20022148D0 (en) Non-viral gene delivery system
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
WO2005051353A3 (en) Pharmaceutical formulations comprising voriconazole

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2498772

Country of ref document: CA

Ref document number: PA/A/2005/002798

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 167405

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003260289

Country of ref document: AU

Ref document number: 2003794821

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003794821

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003794821

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP